The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model
British Journal of Clinical Pharmacology · 06.11.2026
DOI: 10.1002/bcp.70887 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 06.11.2026. Verfasst von Magdalene Zabek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Western University, Children's Health Research Institute, London Health Sciences Research Institute.
Abstract (Originalsprache)
Aims
Nirmatrelvir is an effective therapeutic option for COVID‐19 infection and is often administered after symptom onset in pregnant individuals, but few data are available on the associated fetal exposure. The placental perfusion model evaluates maternal–fetal drug transfer across the human placenta and thus can determine fetal drug exposure. The objective of our study was to quantify the amount of nirmatrelvir transfer across the human placenta using the ex vivo placental perfusion model.
Methods
In a dual closed–closed perfusion of a single human placenta lobule, nirmatrelvir was added to the maternal circulation at its clinical concentration (2.21 μg/mL) or at 10 times this level (22.1 μg/mL). For each placenta studied, there was a 1‐h perfusion control period followed by a 3‐h exposure period. Samples of the perfusate were collected throughout the experiment to measure nirmatrelvir concentrations and placental viability markers.
Results
Perfusions conducted with nirmatrelvir at 2.21 μg/mL ( n = 4) and 22.1 μg/mL ( n = 5) concentrations showed a fetal–maternal concentration ratio (F:M) of 0.34 and 0.42, respectively, at 180 min. F:M was adjusted for nonplacental physiological factors, including binding of albumin and α‐1‐acid glycoprotein, and ionization. The adjusted F:M ranged from 0.26 to 0.35 for placentas perfused with 2.21 μg/mL and from 0.33 to 0.47 for placentas perfused with 22.1 μg/mL of nirmatrelvir.
Conclusions
Nirmatrelvir readily crosses the term human placenta in a concentration‐dependent manner. These transfer kinetics provide a foundation for future physiologically based pharmacokinetic modelling, supporting the development of personalized nirmatrelvir dosing strategies in pregnancy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- London Health Sciences Centre Research Institute, London, Ontario, Canada.
- Children's Health Research Institute, London, Ontario, Canada.
- Department of Paediatrics, Western University, London, Ontario, Canada.
- Department of Obstetrics and Gynecology, Western University, London, Ontario, Canada.
ORCID-Profile: Magdalene Zabek, Eddie Chan, Yong Jin Lim, Bradley L Urquhart, Facundo Garcia-Bournissen, Janine R Hutson
Förderung
- Western University
- Children's Health Research Institute
- London Health Sciences Research Institute
- Innovation Fund of the Alternative Funding Plan of the Academic Health Sciences Centres of Ontario
Zitieren
APA
Zabek, M., Chan, E., Lim, Y. J., Urquhart, B. L., Garcia-Bournissen, F., & Hutson, J. R. (2026). The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70887
Vancouver
Zabek M, Chan E, Lim YJ, Urquhart BL, Garcia-Bournissen F, Hutson JR. The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70887
BibTeX
@article{Zabek2026,
author = {Zabek, Magdalene and Chan, Eddie and Lim, Yong Jin and Urquhart, Bradley L and Garcia-Bournissen, Facundo and Hutson, Janine R},
title = {The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70887}
}
EUVIMED